Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia.
In the register
The register attaches this trial to RCH-01 (RepliCel Life Sciences), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1/2
- Sponsor
- TrichoScience Innovations, Inc.
- Participants (registry)
- 19
- Start
- December 2010
- Primary completion
- April 2012
- Study completion
- February 2017
- Last registry update
- March 2017
- Countries
- Georgia
Conditions studied: Androgenetic Alopecia
Interventions: Human autologous hair follicle cells, autologous hair follicle cells, hair follicle cells, verum, Cell medium, control, placebo, cell transportation medium
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.